Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Basic analyses - work > General > Flashcards

General Flashcards

1
Q

What 3 components to a GLM

A
  1. systemic component - Y = X2
  2. random component - normal distribution, poissan, negative binomial, gamma
  3. link between the two- 1 (normal linear regression) or not 1, puts bend in the line
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how do residuals appear in a standard linear regression model

vs

in a possion or negative binomial regression

A

Standard linear model - assume the reiduals are non normally distributed

in other, residuals form a poissan or negative binomial dsitribution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is OLS?

what is the equation for this

A

Ordinary least squares (OLS) regression include things like:

  • linear regression

predictor = c + Bx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is screening?

A

establishes someones eligibility for the trial

includes
- informed consent
- eligibility assessment
demographics
medical history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is a screening ID

A

soethign given to all n who are screened for the study, regardless of whether they are eligible for the trial or not

those not elkigible or not wishing to continue with the study are classified as “screen failures”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

define adverse event

A

any unexpected medical occurence that may or may not be related to the product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

define adverse reaction

A

unexpected response to an IMP that is related to the dose administered

there must be a reasonable possibility of the event being caused by the IMP i.e. the relationship cannot be ruled out

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is reference saftey information (RSI)

A

a list of medical terms detailing the ARs that are expected from an IMP. This information must be reviewed when assesseing a SAR for expectedness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Serious adverse event (SAE)

A

any unexpected response that
- results in death
- is life threatening
- requires inpatient hospitalisation or prolongation of existing hospitalisation
- results in significant disability/incapacity
- consists of congenital anomaly or birth defect
- anything else that jeopardises n or requires intervention to prevent one of the above consequences

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

serious adverse reaction (SAR)

A

an adverse event that has reasonable possibility to be caused by the IMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Suspected unexpected Serious Adverse Reaction (SUSAR)

A

It is not expected (not consistent with reference saftey information (RSI)), but classed as serious and related to IMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PICO?

A

▪ Population – Who should be included?
▪ Intervention - What is the intervention?
▪ Comparator - Comparing to what?
▪ Outcome - What is “good”?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how do we measure precision or undcertainty wuantitively?

A

o standard error
o confidence interval
o P value

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is standard error

A

a measure of the variability (SD) of sample means in repeated samples from the same population

quantifies how far from teh true (but unknown) population the sample estimate is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are CI

A

o Plausible range of values for the true population value
o In fact, 95% of the times we compute a 95% CI, it will
contain the true (but unknown) population value

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what kind of uncertainty to CI reflect

A

only uncertainty owing to random sampling

Non-sampling errors i.e. biases in design, conduct or analysis not
accounted for

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

relative risk or risk ratio (RR)

A

Is the ratio of the risk of a given event in one
group of subjects compared to another group

18
Q

relative risk reduction

A

– (1-RR) x 100%
– The proportion of the initial or baseline risk
which was eliminated by a given
treatment/intervention or by avoidance of
exposure to a risk factor

19
Q

odds ratio (OR)

A

Is the ratio of the odds of a given event in one
group of subjects compared to another group

20
Q

absolute risk reduction (ARR)

A

The difference in risk of a given event, between
two groups

21
Q

if a drug reduces the risk of a bad outcome from 50% to 40%, the ARR = 0.5 - 0.4 = 0.1

number needed to treat (NNT)

A

It is defined as the number needed to treat in
order to prevent one additional adverse event
(e.g. death)

the NNT = 1/ARR = 10.

22
Q

hazard ratio

A

which is the study of the time it takes for an event of interest, such as death or disease progression, to occur.

compares the risk of the event occurring in two different groups, such as a treatment group and a control group, over a specified period of time.

23
Q

Mediation analysis carried out using what technique?

A

Structual equation modelling.

24
Q

are pilot studies and feasibility studies the same thing?

A

All pilot studies are feasibility studies but not all feasibility studies are pilot studies

25
Q

who are the MHRA?

A

Medicines and Healthcare products Regulatory Agency

if treatment is an drug, then saftey moitoring is the jurisdiction of the UK regulator (MHRA)

26
Q

What is the yellow card scheme

A

after a medical product has been lisenced for use in UK, this scheme is used for collecting and monitoring hte saftey of products

relies on voluntary reporting of side effects of drugs from healthcare providors or wider population

used to signal whether a drug might need to have its saftey checked again

27
Q

which trials involving drug does the saftey reporting fall under the jurisdiction of the MHRA

A

RCT involving a drug

clinical trials ivolving IMP

28
Q

Do we have to report all adverse events

A

yes, requirment within UK regulations to report unexpected AE’s or SAEs.

29
Q

how are AE’s reported

A

MHRA provides specific monitoring and reporting requirments for clinical trials involving IMP

30
Q

what is pharmacovigilance

A

fancy name for The continuous monitoring of the safe use of
medicinal products in clinical trials

31
Q

do we need to include all AE’s in the expadited report?

A

No. depends on how much information is known about current treatment

if we already know a lot about drug. then shoudl focus on including important things, not collating a huge dataset of events that we already know about and expected.

32
Q

when would we collect all vs not all AE’s

A

collects all if early phase drug trial. Less important when drug and AE’s associated are alrerady well documents. Maybe dont collec tthings that we expect.

33
Q

how do we decides which AE’s to report and how is this decided

A

clinical decision but this needs to be approaved by the MHRA.

> How much is known about the intervention?
* Is it being used in a new population?
* Is it a drug being used at a different dose or in combination with other drugs?

> How much data already exists regarding the
safety of the intervention and/or the protocol
driven procedures?

34
Q

can 2 protocols have the same saftey reporting requirments?

A

no

35
Q

when AE is reported how do we determine causality ? if this was from IMP

A
  • Determined with reference to the applicable product
    information
  • Summary of Product Characteristics (SmPC) – licenced product
  • Investigator Brochure (IB) – unlicenced product
  • Protocol - if not IMP, but e.g., a behaivural intervention
36
Q

difference between Serious Adverse
Reaction and Serious Related Event

A

 Serious and related in a CTIMP is a Serious Adverse Reaction
 Serious and related in a non CTIMP is a Serious Related Event

37
Q

what do we refer to when dertermining whether AE was expected?

A

> For non drug trials this would be the protocol
For drug trials this would be the Reference
Safety Information (RSI)
* SmPC for licensed drugs (section 4.8)
* Investigator Brochure (IB) for unlicensed drugs

38
Q

Serious Unexpected and Related Event

A
  • classed as serious
  • related
  • Unexpected in a nonCTIMP
39
Q

who do you report saftey issues to and within what time frame

A

The REC need to know about Serious, Related and Unexpected events (Non-CTIMP) within 15 days of sponsor receiving notification

The MHRA need to know about Suspected,
Unexpected, Serious Adverse Reactions (CTIMP)
* Fatal or life threatening – within 7 days
* Non-fatal and non-life threatening – within 15 days

40
Q

what annual reports are needed?

A

> For non-CTIMPs generate an annual progress report (APR) and submit to REC

> For CTIMPs ensure a Development Safety Update Report (DSUR) is produced and submitted annually to the CA(s) & REC

Basic analyses - work (19 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions